• Market Capitalisation market-capitalisation-info $115 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-72 Mln

Pyxis Oncology Inc (PYXS) Share Price

$1.51

As on 28-Nov-2023 16:00 EST

up-down-arrow $-0.04-2.58%

  • Prev Close info

    $1.55

  • Day's Openinfo

    $1.52

  • Today's Highinfo

    $1.57

  • Today's Lowinfo

    $1.49

  • Today's Volumeinfo

    112,663

  • 52 Week rangeinfo

    $1.10 - 6.92

Please wait...

Pyxis Oncology Inc (PYXS) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Pyxis Oncology Inc (PYXS)
12.69 -3.82 -36.55 -0.66 -- -- --
S&P BSE Sensex*
9.46 4.41 2.46 6.55 14.69 13.27 12.49
S&P Small-Cap 600#
-5.82 -5.34 -13.90 -6.30 5.30 2.98 5.53
As on 28-Nov-2023  |  *As on 29-Nov-2023  |  #As on 26-Oct-2023
2022
Pyxis Oncology Inc (PYXS)
-87.78
S&P Small-Cap 600
-17.42
S&P BSE Sensex
4.44

Valuation

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Pyxis Oncology Inc (PYXS) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Pyxis Oncology Inc (PYXS)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Pyxis Oncology Inc (PYXS)

        Co-Founder & Independent Chairman

        Mr. John L. Flavin M.B.A., MBA, Ph.D.

        CEO, Pres & Director

        Dr. Lara S. Sullivan M.D., MBA

        Headquarters

        Cambridge, MA

        FAQs for Pyxis Oncology Inc (PYXS)

        The total asset value of Pyxis Oncology Inc (PYXS) stood at $ 194 Mln as on 31-Mar-23

        The share price of Pyxis Oncology Inc (PYXS) is $1.51 (NASDAQ) as of 28-Nov-2023 16:00 EST. Pyxis Oncology Inc (PYXS) has given a return of -0.66% in the last 1 years.

        Pyxis Oncology Inc (PYXS) has a market capitalisation of $ 115 Mln as on 09-Jun-2023. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Pyxis Oncology Inc (PYXS) is 0.22 times as on 09-Jun-2023, a -0.91% premium to its peers’ median range of 2.54 times.

        Since, TTM earnings of Pyxis Oncology Inc (PYXS) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Pyxis Oncology Inc (PYXS) and enter the required number of quantities and click on buy to purchase the shares of Pyxis Oncology Inc (PYXS).

        Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

        The CEO & director of Mr. John L. Flavin M.B.A., MBA, Ph.D.. is Pyxis Oncology Inc (PYXS), and CFO & Sr. VP is Dr. Lara S. Sullivan M.D., MBA.

        The promoters of Pyxis Oncology Inc (PYXS) have pledged 0% of the total equity as on Dec-22.

        Pyxis Oncology Inc (PYXS) Ratios
        Return on equity(%)
        -27.57
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        No, TTM profit after tax of Pyxis Oncology Inc (PYXS) was $-72 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $114.76 Mln
        • Revenue (TTM)revenue-information $0.00 Mln
        • Earnings (TTM) earning-information $-72.48 Mln
        • Cash date-information $149.35 Mln
        • Total Debt info $20.25 Mln
        • Insider's Holding 33.29%
        • Liquidity liquidity High
        • 52 Week range week-range $1.10 - 6.92
        • Shares outstanding share-outstanding 38,252,200

        About The Company

        • IPO Date 08-Oct-2021
        • Co-Founder & Independent Chairman Mr. John L. Flavin M.B.A., MBA, Ph.D.
        • CEO, Pres & Director Dr. Lara S. Sullivan M.D., MBA
        • Listing key-listing NASDAQ: PYXS
        • Country United States
        • Headquarters headquarters Cambridge, MA
        • Website website https://www.pyxisoncology.com
        • Business

          Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15...  targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.  Read more

        Demystifying Stocks.

        At Value Research, we believe it's best to understand investments before diving in. And since 1990, we've been doing exactly that – helping & guiding lakhs of Indians with their investing journey. Join the journey.

        Sign Up for Free
        demystifying-mutual-fund

        What can Value Research do for you?

        solidify-your-fundamentals
        Solidify your fundamentals

        Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.

        track-all-your-investments
        Track all your investments

        Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.

        get-guidance-from-our-experts
        Get guidance from our experts

        Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.

        get-access-to-exclusive-analytics
        Get access to exclusive analytics

        Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.

        Explore it yourself, for free

        Sign up and get access to:

        Unlimited access to advice from India's top experts

        The most comprehensive analysis of funds and stocks in India

        A holistic portfolio manager to help track all your investments easily

        And much more, like guides, tools, webinars, videos and eBooks.

        share-fund-plan-icon